Abstracts tagged "Erdheim-Chester disease"

Abstract Number: 372 • 2018 ACR/ARHP Annual Meeting
Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study
Michel Villatoro-Villar¹, Michael Bold², Kenneth J. Warrington³, Cynthia S. Crowson⁴, Gaurav Goyal⁵, Mithun Shah⁵, Ronald Go⁵ and Matthew J. Koster¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Radiology, Mayo Clinic, Rochester, MN, ³Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Hematology, Mayo Clinic, Rochester, MN
Background/Purpose: Erdheim-Chester disease (ECD) is a rare histiocytosis of the “L” (Langerhans) group with multisystem involvement that can affect the large and medium sized arteries…
Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting
Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease
Giulio Cavalli¹, Alvise Berti¹, Barbara Gulgielmi¹, Marco Gelpi², Riccardo Biavasco², Corrado Campochiaro¹, Alessandro Tomelleri², Marina Ferrarini³, Maria Grazia Sabbadini² and Lorenzo Dagna², ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Department of Oncology, San Raffaele Scientific Institute, MIlan, Italy
Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…
Abstract Number: 225 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Involvement In Erdheim-Chester Disease: A Magnetic Resonance Imaging Study On Seven Patients
Enrica Rossi¹, Lorenzo Buttarelli¹, Augusto Vaglio², Davide Gianfreda³, Chiara Martini¹ and Massimo De Filippo¹, ¹Radiology, University of Parma, Parma, Italy, ²Unit of Nephrology, University Hospital of Parma, Parma, Italy, ³University of Parma, Parma, Italy
Background/Purpose: Erdheim-Chester Disease (ECD) is a rare non-Langherans form of histiocytosis, characterized by xanthomatous or xanthogranulomatous infiltration of tissues by foamy histiocytes, surrounded by fibrosis.…
Abstract Number: 751 • 2012 ACR/ARHP Annual Meeting
Whole Transcriptome Analysis in Erdheim-Chester Disease: A Multicenter Collaborative Study of 58 Patients
Laurent Arnaud¹, Julien Haroche², Lorenzo Dagna³, Augusto Vaglio⁴, Bruno Faivre⁵, Karim Dorgham⁵, Baptiste Hervier⁶, Fleur Cohen-Aubart⁷, Guy Gorochov⁸ and Zahir Amoura¹, ¹Internal Medicine, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ³Vita-Salute San Raffaele University, Milan, Italy, ⁴Unit of Nephrology, University Hospital of Parma, Parma, Italy, ⁵Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France, ⁶Internal Medicine I & II, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, ⁷Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁸Inserm UMRS945, Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France
Background/Purpose: To date, gene expression profiling has not been performed in Erdheim-Chester disease (ECD), a rare, non-Langerhans form of histiocytosis. The aim of this study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].